Rentsch CA, Hayoz S, Cathomas RL. Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study. Eur Urol 2022 Jan 24. pii: S0302-2838(22)00022.
PMID: 35086721